Skip to main content

National Cancer Institute — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

102
Companies
$325.9M
Total invested
$3.4M
Avg. check
25
Industries
Biotechnology 19Health Care 15Therapeutics 7Medical Device 6Pharmaceutical 6Life Science 5+19 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 102
CellsBin
October 2026

CellsBin is a VC-backed startup that offers drug discovery, immunotherapy, and toxicity testing.

3D Technology · New Haven$2.1M Grant
Xylyx Bio
October 2026

Xylyx Bio creates effective science-based solutions for the benefit of human life and health.

Biotechnology · Brooklyn$3.0M Grant
Senticell
September 2026

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat diseases.

Artificial Intelligence (AI) · PrincetonGrant
Intus Bio
September 2026

Intus Bio develops biotechnology solutions centered on microbiome analysis and diagnostic discovery.

Bioinformatics · Farmington$2.7M Grant
MALCOVA
September 2026

MALCOVA is a medical device startup delivering novel hardware and AI-based software solutions to resolve needs in the radiology market.

Health Diagnostics · Newark$1.2M Seed
AiM Medical Robotics
September 2026

AiM Medical Robotics is a biotechnology company developing a robotic system for use in neurosurgical procedures.

Biotechnology · Worcester$8.1M Grant
QT Imaging
May 2026

QT Imaging is a scanning center that provides breast imaging by tomographic transmission ultrasound for patients.

Health Care · Novato$10.0M Post-IPO Equity
Quiver Bioscience
May 2026

Quiver Bioscience develops medicines for brain disorders using human disease models and advanced AI technologies.

Artificial Intelligence (AI) · Cambridge$9.3M Grant
Transcode Therapeutics
April 2026

TransCode Therapeutics is an RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer.

Biotechnology · Newton$6.0M Post-IPO Debt
Sinopia Biosciences
March 2026

Sinopia Biosciences enables data-driven drug discovery by means of multi-omics data, machine learning, network analyses, and disease models.

Artificial Intelligence (AI) · San Diego$400K Grant
Linnaeus Therapeutics
February 2026

Linnaeus Therapeutics is a development stage biotech company that develops and commercializes drugs for cancer.

Biotechnology · Haddonfield$5.0M Venture - Series Unknown
Vivere Oncotherapies
January 2026

Vivere develops targeted cancer therapies that activate the immune system to detect and destroy tumors using engineered bio-platforms.

Biotechnology · Berkeley$10.0M Seed
Trethera
December 2025

Trethera is a biotechnology company that discovers and develops small molecules that control DNA replication and integrity.

Biotechnology · Beverly Hills$2.7M Grant
Paramita Therapeutics
November 2025

Paramita Therapeutics is a biotech company that focuses on developing new cancer and infectious disease therapeutics.

Biotechnology · San Diego$353K Grant
RIVANNA
October 2025

RIVANNA commercializes ultrasound technologies that reduce the patient risk caused by radiation from X-ray-based medical imaging.

Biotechnology · Crozet$3.0M Grant
Veramorph
October 2025

VeraMorph is a pharmaceutical company that is developing an oral dosage technology based on polymers.

Biotechnology · MansfieldGrant
Allterum Therapeutics
September 2025

Allterum Therapeutics is a biopharmaceutical company that develops treatments for different types of cancers.

Biopharma · Houston$1.0M Grant
Navrogen
September 2025

Navrogen is a biopharmaceutical company that focuses on the targeted treatment of cancer.

Biotechnology · PhiladelphiaGrant
MetasTx LLC
July 2025

MetasTx is creating treatments that prevent and treat prostate cancer metastasis without affecting the Androgen System.

Manufacturing · Basking Ridge$400K Grant
Lamassu Pharma
June 2025

Lamassu Pharma is a biotech startup that solves the critical unmet medical need for severe acute pancreatitis.

Biotechnology · Durham$2.7M Grant
mPath Health
February 2025

mPath Health is a cloud-based automation software platform that helps to improve preventive care.

Health Care · Winston SalemNon-equity Assistance
Navega Therapeutics
February 2025

Navega Therapeutics is a preclinical stage company developing epigenetic gene therapies for neurological and ophthalmic diseases.

Biopharma · San Diego$4.0M Grant
Resolute Science
February 2025

Resolute is advancing a first-in-class platform of cytotoxics and radiotherapeutics for aggressive and hard to treat solid tumors.

Biotechnology · San DiegoVenture - Series Unknown
ZetaGen Therapeutics
January 2025

ZetaGen Therapeutics commercializes a small molecule-based osteoinductive platform.

Health Care · Syracuse$12.9M Series B

Where National Cancer Institute invests

Biotechnology19
Health Care15
Therapeutics7
Medical Device6
Pharmaceutical6
Life Science5

About National Cancer Institute's portfolio

How many companies has National Cancer Institute invested in?▸

National Cancer Institute has invested in 102 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does National Cancer Institute invest in?▸

National Cancer Institute's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical Device, Pharmaceutical. The firm invests across 25 different industry categories.

What is National Cancer Institute's largest investment?▸

Among tracked funding rounds, ZetaGen Therapeutics received $12.9M in a Series B round. National Cancer Institute's total known invested capital is $325.9M.

What is the average investment size for National Cancer Institute?▸

National Cancer Institute's average investment size is $3.4M across its portfolio of 102 companies.

What are National Cancer Institute's most recent investments?▸

Recent National Cancer Institute portfolio additions include CellsBin, Xylyx Bio, Senticell, Intus Bio, MALCOVA. These companies were founded in 2020 or later.

Reach the founders behind these 102 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →